Back to today’s briefing

Story perspectives

Novo Nordisk Sues Eli Lilly Over Weight-Loss Ad Claims

7/21/2026

43 8 Full Breakdown

Summary

Story summary

Novo Nordisk sued Eli Lilly in New Jersey court, alleging false advertising of weight-loss drugs.
Novo says Lilly’s ads compare doses of Mounjaro and Zepbound with doses of Wegovy and Ozempic, omitting options.
Novo seeks an injunction to pull the ads and run messaging.
Lilly says the ads are truthful, based on scientific evidence and will be defended.
After filing, the stocks moved, with Novo down 2% and Lilly up 0.5%.

1 of 1

Story summary

Novo Nordisk sued Eli Lilly in New Jersey court, alleging false advertising of weight-loss drugs.
Novo says Lilly’s ads compare doses of Mounjaro and Zepbound with doses of Wegovy and Ozempic, omitting options.
Novo seeks an injunction to pull the ads and run messaging.
Lilly says the ads are truthful, based on scientific evidence and will be defended.
After filing, the stocks moved, with Novo down 2% and Lilly up 0.5%.